Behavioral and psychiatric comorbidities are common in #epilepsy. Dr. Waldron (@dgsomucla) reviews evidence-based options, from SSRIs and antipsychotics, to #ADHD medications and ASMs that support mood and behavior. https://t.co/xtQY5sPuXN @amepilepsysoc @UCLAHealth

DEE-SWAS remains difficult to treat, with heterogeneous presentations, variable responses, and urgent need for standardized approaches to therapy and outcome measurement. In a new review article, Drs. Rao (@lmraomd), Stowe, Kelley, Pavuluri, Liu, & Patel examine current

New adapted clinical practice #guidelines for the outpatient management of #TBI have been published in @AnnFamMed. https://t.co/dhZo8qlaCC @biaamerica @AANmember @I_B_I_A @ACPIMPhysicians

The @US_FDA has granted Fast Track Designation to #cladribine capsules (@EMDGroup) for the treatment of people with generalized #Myasthenia #Gravis. https://t.co/giHDfRn5On @MyastheniaOrg @AANEMorg @AANmember #gMG

Minimally invasive surgery within 72 hrs did not significantly improve 6-month disability or reduce 30-day mortality vs medical management alone in patients with supratentorial #ICH. Data published in @JAMANeuro. https://t.co/DRfDCp1Hml @EVToday @WorldStrokeOrg @American_Heart

New findings from ancillary US #POINTER studies show structured lifestyle interventions linked to #sleep apnea, #neurovascular health, and #cognitive resilience in older adults at risk for #Alzheimer’s—#CTAD2025 https://t.co/jH2nm0pdyW @ctadconference @alzassociation @AANmember

The diagnostic accuracy of #Fujirebio's #Lumipulse plasma assay for #Alzheimer's pathology was assessed in a real-world cohort in a study presented at #CTAD2025. https://t.co/YhkL4yITnX @US_FDA @ctadconference @AANmember @Alzassociation

Treatment with the anti-#tau antibody #etalanetug in people with dominantly inherited #Alzheimer disease was associated with substantial reductions in the novel #biomarker eMTBR-tau243, indicating strong target engagement. #CTAD2025 https://t.co/Zunbh9xip4 @ctadconference

LM11A-31, a p75 neurotrophin receptor modulator, reduced p-#tau217 and preserved visuospatial function in #Alzheimer disease, with proteomic changes linked to synaptic biology. Data presented at #CTAD2025. https://t.co/awEdQmLfae @CTADConference @alzassociation @AANmember

At #CTAD2025, Takeshi Iwatsubo, MD, PhD was honored as the recipient of this year’s Lifetime Achievement Award in #Alzheimer’s Disease Therapeutic Research. https://t.co/XxI4J8BB4p @CTADconference @alzassociation @NCNP_PR

An oral #amyloid oligomer-targeting treatment was associated with cognitive and functional benefits in APOE ε4 homozygotes with MCI, according to results presented at #CTAD2025 https://t.co/gi3CaYwnzv @Alzheon @CTADconference @alzassociation

In Lennox-Gastaut syndrome, #neuromodulation approaches—including #VNS, #DBS, and #RNS—offer substantial, durable #seizure reduction when medications fail. Dr Edmonds (@Edmondsbd) discusses these strategies in an article: https://t.co/QHE4pvsnt5 @amepilepsysoc @AANmember

One API. Send messages on all channels.

An individual with progressive gait, cognitive, & cranial nerve symptoms had imaging consistent with intracranial hypotension, but repeated CTM/DSM found no #CSF leak. A fractured #cranioplasty implant was identified as the cause in a case report by Drs. Kushwah, Tiwari, Chhabra,

The @US_FDA has approved #Itvisma (@Novartis) for people aged ≥2 years with #spinalmuscularatrophy and an SMN1 mutation—expanding gene-replacement therapy options for #SMA. https://t.co/ct9ecoEPSA @CureSMA @SMANewsToday @AANmember @ChildNeuroSoc

Once-daily #asundexian + #antiplatelet therapy reduced #ischemic #stroke risk vs placebo with no rise in ISTH major bleeding in people with noncardioembolic ischemic stroke or high-risk TIA. https://t.co/QXKzMLuHjI @WorldStrokeOrg @American_Stroke @EVToday

Strategies for managing drug-resistant #epilepsy are expanding with advances in less-invasive surgery—innovations in #SEEG, laser ablation, and #neuromodulation are broadening candidacy. Drs. Gallagher and Fallah (@a__fallah) review these technologies and their applications:

Updated consensus guidelines for the use of peripheral nerve stimulation in chronic #pain and certain #neurologic indications have been published by @ASPN_PainNeuro in @JPainResearch. https://t.co/2KyI2BnT3E @AANmember

Treatment with @VyeptiHCP (#eptinezumab; @LundbeckUS) was shown to significantly reduce monthly #migraine days vs placebo in adults with chronic migraine, according to data published in @JCephalagia. https://t.co/Hnq0VqFhDe @ahsheadache @amfmigraine @AANmember

#Neuroinflammation plays a key role in refractory/super-refractory status #epilepticus. Drs. Silverman, Nagesh, Ho, and Santoro (@Drjonsantoro) outline the current understanding of immunotherapeutic and #immunomodulatory agents for the management of RSE. https://t.co/kpWMOkUrXm

The @US_FDA has granted 510(k) clearance to 2 devices developed by @Vesaliocom for use in peripheral and neurovascular #thrombectomy aspiration. https://t.co/otlhCFnYXU @EVToday @AANmember @WorldStrokeOrg #Stroke